2-carboxyarticaine: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 163921 |
| SCHEMBL ID | 9412742 |
| MeSH ID | M0157005 |
| Synonym |
|---|
| STK993692 |
| 4-methyl-3-[(n-propylalanyl)amino]thiophene-2-carboxylic acid |
| 2-carboxyarticaine |
| 114176-52-2 |
| AKOS016896723 |
| AKOS001275570 |
| 4-methyl-3-[2-(propylamino)propanoylamino]thiophene-2-carboxylic acid |
| articainic acid |
| 2-thiophenecarboxylic acid, 4-methyl-3-((1-oxo-2-(propylamino)propyl)amino)- |
| unii-99r4wp7qc7 |
| 99r4wp7qc7 , |
| articaine acid |
| 4-methyl-3-(((2rs)-2-(propylamino)propanoyl)amino)thiophene-2-carboxylic acid |
| articaine hydrochloride impurity b [ep impurity] |
| SCHEMBL9412742 |
| 4-methyl-3-[[1-oxo-2-(propylamino)propyl]amino]-2-thiophenecarboxylic acid |
| 4-methyl-3[2-(propylamino) propionamido]-2-thiophenecarboxylic acid |
| articaine impurity b |
| DTXSID50921296 |
| 3-{[1-hydroxy-2-(propylamino)propylidene]amino}-4-methylthiophene-2-carboxylic acid |
| Z208191974 |
| 2-thiophenecarboxylic acid, 4-methyl-3-[[1-oxo-2-(propylamino)propyl]amino]- |
| Q27272234 |
| EN300-23752128 |
| 4-methyl-3-[2-(propylamino)propanamido]thiophene-2-carboxylic acid |
| Excerpt | Reference | Relevance |
|---|---|---|
| " Pharmacokinetic parameters are given." | ( Clinical effects and pharmacokinetics of articainic acid in one volunteer after intravenous administration. Baars, AM; Booij, LH; Termond, EF; Van Oss, GE; Vree, TB, 1988) | 0.27 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 3 (42.86) | 18.7374 |
| 1990's | 4 (57.14) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.31) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 8 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||